FeliciaCosmanMD

Endocrinology • West Haverstraw, NY

Diabetes, Lipid Metabolism

Professor of Medicine, Columbia P&S

Join to view full profile

Dr. Cosman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cosman's full profile

Already have an account?

Office
51 S Route 9w
Helen Hayes Hospital
West Haverstraw, NY 10993
Phone+1 845-786-4494

Fax+1 845-787-4878

Education & Training

New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1983 - 1988
Stony Brook University Health Sciences Center School of MedicineClass of 1983

Certifications & Licensure

NY State Medical License 1985 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

Top Doctors: New York Metro Area Castle Connolly, 2002-2014
Hudson Valley Magazine Castle Connolly, 2007-2013
New York Magazine: Top Doctors Castle Connolly, 2002

Clinical Trials

Parathyroid Hormone (PTH) With Alendronate for Osteoporosis Start of enrollment: 1987 Sep 01
Completed
Phase 2
Early Effects of Parathyroid Hormone (PTH) on the Proximal Femur Start of enrollment: 2010 Aug 01
Completed
Not Applicable
The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab Start of enrollment: 2013 Aug 01
Unknown status
Phase 4

Publications & Presentations

PubMed

34 citations
Vitamin D economy in blacks.
Felicia Cosman, Jeri W. Nieves, David W. Dempster, Robert Lindsay
Journal of Bone and Mineral Research. 2007-12-01
551 citations
Anabolic Actions of Parathyroid Hormone on Bone
David W. Dempster, Felicia Cosman, May Parisien, V. Shen, Robert Lindsay
Endocrine Reviews. 1993-12-01
36 citations
Combination therapy for osteoporosis: a reappraisal
Felicia Cosman
Bonekey Reports. 2014-04-02

Authored Content

Abaloparatide: An Anabolic Treatment to Reduce Fracture Risk in Postmenopausal Women with OsteoporosisOctober 2020

Press Mentions

Highlights from the ACR Review Course 2022December 6th, 2022
Conference aids2022 HighlightsOctober 27th, 2022
ACR 2020: 100+ Arthritis and Rheumatic Disease Updates Patients Must Know AboutNovember 25th, 2020
Join now to see all